TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05332340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BZ371A
Description: Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
Study: NCT05138575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin + Potassium Chloride
Description: Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin + Potassium Nitrate
Description: Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Potassium Chloride + Placebo for Empagliflozin
Description: Active control.
Study: NCT04834427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional therapy + S (+)-Ketamine
Description: In principle, there are no specific restrictions on the dosage, mode of administration, timing, and compatibility of S-ketamine hydrochloride injection, but the recommended dosage is given, which is lower than the dosage specified in the instructions.~Recommended use and dosage of S (+)-Ketamine:~1. Intravenous injection：Bolus intravenous injection before skin incision, the dose is 0.1\~0.25 mg/kg; Bolus intravenous injection (dose 0.1\~0.25 mg/kg) before skin incision + continuous intravenous infusion (dose of 0.1\~0.25 mg/kg/h) during operation; Continuous intravenous infusion after surgery with a dose of 0.02\~0.1 mg/kg/h for 24\~48 h.~2. Intramuscular injection：The dose is 2\~4 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Study: NCT05252000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical debridement
Description: subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical debridement
Description: subjects will receive traditional non-surgical mechanical debridement of tooth surfaces with scalers and ultrasonics removing supragingival and subgingival plaque

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: adjunctive aPDT
Description: Antimicrobial photodynamic therapy will be done at tooth sites by applying a photosensitizing dye methylene blue (0.1mg/ml) with a disposable syringe from the bottom of pocket in a coronal direction. After 3 minutes in situ, the surrounding gingival tissues will be irradiated at six sites around the tooth using a diode laser with a wavelength of 660nm, providing an energy density of 10 J/site, 100mW power, time equal to 100 seconds. After irradiation, the site will be thoroughly rinsed with saline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham aPDT
Description: subjects will receive saline and non-light emitting laser on the tooth
Study: NCT05536258

Intervention type: OTHER
Intervention: Fluid
Description: The investigators will titrate fluid administration to maintain a RI \> 90 over at least 85% of the intraoperative period lasting from induction until the end of anesthesia. Specifically, the investigator will consider titration to have been successful if 85% of patients in the RI group sustain a RI \> 90 over at least 85% of the intraoperative period.
Study: NCT06346964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education prepared for chronic disease self-management aims to improve the health behaviors of older adults.
Study: NCT05256342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 60mg
Description: Eight weeks treatment, one pill daily.~1st week 30mg; weeks 2-7th -- 60 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 60 mg
Description: One pill daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazol
Description: 20 mg daily; will be taken with Etoricoxib from the second week of treatment
Study: NCT06204861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capacitive and Resistive Electric Transfer Therapy
Description: Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: The training program consists of five exercises: single-limb stance, single-limb stance with ball toss, single-limb stance with kicking, step-down with a single-limb stance, and wobble board. The program is conducted three times a week, and the difficulty level is increased every two weeks. Before and following the training, a physiotherapist will lead a warm-up and stretching session.
Study: NCT04745065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect2BWell
Description: Please see the description provided for arm 1.
Study: NCT05882435

Intervention type: OTHER
Group type: OTHER
Intervention: Organization with AI
Description: X-rays are done in the radiology department and the images are made available to emergency physicians with the AI interpretation. X-rays flagged by IA as anormal or suspicious will be reviewed without delay by the radiologist, non-flagged X-rays will be reviewed by radiologists on a delayed basis.
Study: NCT05230966

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: RIC is a non-invasive method that achieves a state of intermittent hypoxia, and is performed by inflating the cuff of the pressure gauge on the left upper arm to 200 mmHg in 4 episodes of five-minute ischemia and reperfusion alternately for 45 minutes.
Study: NCT06204861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training Combined with Capacitive and Resistive Electric Transfer Therapy
Description: Participants received a 10-minute intervention in CAP mode followed by a 20-minute intervention in RES mode. However, the B+CRET group received balance training along with CRET treatment.
Study: NCT06021275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling with topical application of regular insulin
Description: Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling with topical application of saline
Description: Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group
Study: NCT05305391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: The arising gastrointestinal symptoms and inflammation markers from consumption of milk + lactase capsule / placebo.
Study: NCT05449366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Paclitaxel Solution (Ml)
Description: Weekly cycles of intraperitoneal paclitaxel monotherapy
Study: NCT05467566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Exercise protocol + application of active direct current stimulation for 30 minutes.
Study: NCT04806347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft
Description: After undergoing a disease specific conditioning regimen (standard of care), participants will receive peripheral blood stem cell transplant from a haploidentical donor or closely matched unrelated donor, depleted of TCR αβ+ and CD19+ cells using the CliniMACS TCR α/β-biotin and CD19 Systems.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS® System
Description: The CliniMACS Cell Selection System is based on magnetic-activated cell sorting mechanism. The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures.
Study: NCT06571994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Plastic Intervention
Description: Participants will be provided with food that contain no or low plastic and PAC. This is defined as minimally processed (according to NOVA Classification) fresh produce where the supply chain is either known to be free, or likely to be free of plastic contamination. Foods that are canned, pickled, use plastic storage containers will be either avoided or substituted where possible with glass. Participants will also follow guidance concerning the preparation of their food. Plastic utensils used in the preparation of food will be substituted for non-plastic. Commonly used personal care products, e.g., shampoo and soaps, and cleaning products will be replaced with no/low PAC alternatives. Participants will be supplied with a comprehensive schedule, and instructions for the 4-week intervention.
Study: NCT05162131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 100 mg or Placebo
Description: Experiment 1-a: 100 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 300 mg or Placebo
Description: Experiment 1-b: 300 mg Bentracimab (PB2452) (no Placebo, no Ticagrelor)~Drug: PB2452 infusion 30 minute - 12-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 1000 mg or Placebo
Description: Experiment 1-c: 1000 mg Bentracimab (PB2452) or Placebo (no Ticagrelor)~Drug: PB2452 Infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment)
Description: Experiment 2: 1000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment)
Description: Experiment 3: 3000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment)
Description: Experiment 4: 9000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)
Description: Experiment 5: 18000 mg Bentracimab (PB2452) or Placebo (Ticagrelor Pre-treatment)~Drug: PB2452 infusion 30 minute - 12-hour infusion~Drug: Placebo - Sodium Chloride 30 minute - 12-hour infusion~Drug: Ticagrelor Oral Tablet - Pre-treatment Ticagrelor 180 mg + 90 mg bid for 5 doses prior to PB2452 or Placebo
Study: NCT05341895

Intervention type: OTHER
Group type: OTHER
Intervention: Kinesiotape
Description: Taping
Study: NCT05467566

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial direct current stimulation
Description: Exercise protocol + application of simulation of direct current stimulation for 30 minutes. The stimulator will be turned off after 30 seconds and the volunteers will not receive current for the rest of the session.
Study: NCT05057884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: Slow nasal breathing with intermittent end-expiratory apnoea for 15 min twice per day over 12 weeks.
Study: NCT05391295

Intervention type: OTHER
Intervention: Short daily questionnaire
Description: This study includes 1 survey that needs to be filled out by the patient on his/her phone daily during the course of corticosteroid treatment. The investigators will start the survey few days before the corticosteroid treatment and it will continue till the end of the treatment regime. The treatment regime is regular care and patient specific, but will approximately have a duration of 40 days. In case of prolonged treatment with steroids it is decided to have a limit for our study: either until 7 days after the end of corticosteroid treatment or a maximum of 60 days.
Study: NCT05407376

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Produce prescription (weekly produce delivery)
Description: Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Produce prescription (weekly produce delivery)
Description: Participants will receive weekly produce deliveries and recipes sent directly to their homes for 6 months.
Study: NCT05219006

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic dieting
Description: Atkins modified diet: 1.2-1.5 g/kg/day of protein with a ratio 1:1 (fat: carbohydrate + protein)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: healthy dieting
Description: Normocaloric diet established by a nutritionist. 1.2-1.5 g/kg/day of protein with a maximum contribution of 50 % carbohydrates of the total calorie intake eliminating industrialized food.
Study: NCT05571852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CogniFit's CCT Post COVID-19
Description: The computerized cognitive training (CCT) program is tailored to each person's specific cognitive strengths and weaknesses detected in the Cognitive Assessment Battery (CAB)™ PRO (CogniFit Inc., San Francisco, US; https://www.cognifit.com/cab) by a patented Individualized Training System™ (ITS) software.
Study: NCT04796688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
Study: NCT03733028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Intervention for Reducing Anger (MIRA)
Description: This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Intervention
Description: This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance.
Study: NCT04713904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Test Product Coated Tablets
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clormadinone 2 mg and Ethinyl estradiol 0.02 mg Reference Product Coated Tablets
Description: Evafem 20 (Trademark)
Study: NCT05084560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AWZ1066S
Description: Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06086860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with dry needling.
Description: The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan mobilization without dry needling
Description: The duration of intervention will be 6 weeks, 2 sessions a week, a total of 12 sessions will be given to the study participants. Each session will last for 30 minutes.
Study: NCT04124458

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
Study: NCT05290454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mNGS-guided treatment
Description: mNGS detect the causative microorganisms using appropriate lower respiratory tract (LRT) specimen. LRT specimen, such as endotracheal aspiration (ETA), bronchoalveolar lavage fluid (BALF), or protected specimen brush (PSB), will be obtained within 24 hours after the participants entering the ICU. Clinicians apply the definitive treatment based on mNGS results, as well as results of conventional microbiology diagnostic techniques.
Study: NCT05479344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection
Description: The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A Brief Contextual Behavioural Intervention Based on Strengths, Meaning, Hope and Connection
Description: The intervention strategy combines acceptance and commitment therapy, contextual behavioral science, and positive psychology interventions (strengths, meaning, hope) in the form of a single intervention set (each topic is a single 90-minute intervention, four single intervention combinations).
Study: NCT04927767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: denture adhesive
Description: Denture adhesive is a commercially available denture care product used to adhere a denture to the oral mucosa, in order to improve the retention and stability.
Study: NCT04318691

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Blood sampling at baseline and at day-3 (10 ml, EDTA tube), test of NETs.

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage at admission to the ICU with analysis of cytological, bacteriological, viral and anatomopathological, and test of NETs.
Study: NCT05958966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette e-liquid self-administration
Description: Participant will self-administer an experimenter-provided e-cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette e-liquid self-administration
Description: Participant will self-administer an experimenter-provided e-cigarette.